Archives

Ozempic Is Shrinking More Than Waistlines, It’s Slashing Americans’ Food Bills

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far beyond individual health. When people in the United States begin using appetite-suppressing medications such as Ozempic and Wegovy, the effects can reach far beyond changes in body weight. New research from Cornell University suggests that […]

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

Key Points Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. 10 stocks we like better than Eli Lilly › Over the past few years, Eli Lilly (NYSE: […]

$NVO Quality GIGA-LONNNNNNNGGGGG!!!

$NVO Quality GIGA-LONNNNNNNGGGGG!!! Novo Nordisk A/S Sponsored ADR Class B BATS:NVO MrJosephTrades This is a weekly of NVO, a global leader in pharmaceuticals addressing issues like obesity, diabetes, among other things. Ever hear of Ozempic? This company makes it. They also have other products in their pipeline which intend to capitalize on these growing epidemics, […]

How weight-loss drugs are reshaping fitness gyms – Axios

How weight-loss drugs are reshaping fitness gyms  Axios 87% of Doctors Say Obesity Drugs Help Patients  동아비즈니스리뷰 | DBR Korea weighs reimbursing GLP‑1 obesity drugs amid rising prevalence and cost concerns – CHOSUNBIZ  Chosunbiz “Do You Want to Lose Weight?” “I’ll Take Wegovy”… Gyms Break Out in a Cold Sweat  아시아경제 The end of the year and the beginning […]

Medicina, Vol. 62, Pages 41: Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial

Medicina, Vol. 62, Pages 41: Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial Medicina doi: 10.3390/medicina62010041 Authors: Janvier Youovop Guy Takuissu Régine Minoue Felix Nwang Maryam Adegboyega Crista Arrey Inelle Makamwe Julius Oben Background and Objectives: Dichrostachys glomerata and Cissus […]

Weight-Loss Drugs Are Changing. Here’s What to Know – Bloomberg.com

Weight-Loss Drugs Are Changing. Here’s What to Know  Bloomberg.com Weight-loss pill approval set to accelerate food industry product overhauls  Reuters U.S. regulators approve Wegovy pill for weight loss  NPR FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss  The American Journal of Managed Care® (AJMC®) The FDA just approved the first GLP-1 weight-loss pill. Here’s what to […]

Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes of patients with T2D and CKD in China who initiated sodium-glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RA). Design Retrospective cohort study. Setting […]

Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinsons disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study

Introduction Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet been established and remains controversial. This clinical study aims to assess the efficacy, disease-modifying effects, safety and optimal dose of oral semaglutide tablets, a GLP-1 receptor agonist, in idiopathic patients with […]

Weight-loss pill approval spurs food industry overhaul | REUTERS

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say. #News #USA #WeightLoss #GLP #Reuters #Newsfeed Read the story here: https://reut.rs/4atbzuB 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest news from around the world: https://www.reuters.com/ Follow […]